Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for brain and centrally mediated diseases. Its pipeline includes small-molecule drug candidates for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, obesity, and other neuroscience targets.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2022–2025
Liiketoiminta
Osuus liikevaihdostaLate-stage and early clinical drug candidates for psychiatric and neurologic disorders.
Discovery-stage programs targeting novel CNS mechanisms and disease pathways.
Internal research efforts, target validation, and translational neuroscience work.
Asiakkaat
Neumora does not currently sell commercial products; its near-term “customers” are clinical trial participants, investigators, and ultimately regulators and payers that determine whether its drug candidates can reach patients. If approved, its therapies would be used by physicians treating patients with major depressive disorder, Alzheimer’s-related agitation, obesity, and other CNS disorders.
Patients and healthy volunteers enrolled in Phase 1, 1b, and Phase 3 studies to generate safety and efficacy data.
Physicians and clinics that would prescribe navacaprant for major depressive disorder if approved.
Specialists treating agitation associated with dementia due to Alzheimer’s disease, the target for NMRA-511.
Clinicians who may use NMRA-215 for obesity if clinical development and approval succeed.
Strategia
Neumora’s strategy is to build a differentiated neuroscience pipeline around novel mechanisms of action for underserved brain diseases. The company is prioritizing late-stage development of navacaprant, advancing NMRA-511 and M4 PAM programs, and expanding into additional CNS and metabolic targets such as NMRA-215.
This is the most advanced program and the clearest path to potential first commercialization.
Positive signal-seeking data would support expansion into Alzheimer’s-related agitation.
Multiple compounds diversify the pipeline and broaden the company’s neuroscience platform.
Adds a new therapeutic area and another novel mechanism to the pipeline.
Maantiede
Neumora is headquartered in the United States and conducts its research and development from U.S.-based operations, including office space in Massachusetts. Its business is currently centered on U.S. clinical development and regulatory pathways, with future commercialization dependent on approvals in the U.S. and potentially other markets.
Riskit
Neumora faces the typical risks of a clinical-stage biotech company: long development timelines, uncertain trial outcomes, and heavy dependence on regulatory approval. Because it has no commercial products, its future value depends on successful clinical data, intellectual property protection, and access to capital to fund ongoing development.
- Clinical development failure or delayVaikutus: KriittinenTodennäköisyys: Korkea
Drug candidates may not show sufficient safety or efficacy, or trials may take longer than planned.
Kohdistuu - Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
FDA or foreign authorities may require additional data or reject applications.
Kohdistuu: All pipeline programs
- Capital and dilution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company has no product revenue and must fund R&D through external capital.
Kohdistuu: Corporate funding needs
- Intellectual property and licensing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Loss of licensed rights or disputes could impair development and commercialization.
Kohdistuu: In-license agreements and acquired technologies
Kirjanpito
Harkinnanvaraiset erätPrior acquisitions created significant intangible asset-related charges and future valuation sensitivity.
Vaikutus: Can materially affect operating results and balance sheet carrying values
Future payments depend on clinical, regulatory, and commercial events and may require fair value estimates.
Vaikutus: Can create volatility in liabilities and earnings
Office leases create right-of-use assets and lease liabilities that affect reported leverage and expenses.
Vaikutus: Impacts balance sheet and operating expense presentation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Neuphoria Therapeutics Inc.
NEUP · Pharmaceutical Preparations
CervoMed Inc.
CRVO · Pharmaceutical Preparations
Damora Therapeutics, Inc.
DMRA · Pharmaceutical Preparations
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
Minerva Neurosciences, Inc.
NERV · Pharmaceutical Preparations
Päivitetty: 24.9.2026